Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: An in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy
Jre. Davis et al., Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: An in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy, ENDOCRINOL, 142(2), 2001, pp. 795-801
Ablative therapies for pituitary tumors commonly cause irreversible damage
to normal pituitary cells. Toxin gene therapy should therefore ideally be t
argeted to specific cell types to avoid collateral cell damage. To evaluate
cell-type-specific adenoviral gene transfer in the intact pituitary gland
we have used stereotaxic transcranial delivery of recombinant adenoviruses
in the sheep with continuous assessment of endocrine function. Adenoviral b
eta -galactosidase expression was driven either by the human cytomegaloviru
s (hCMV) promoter or the human PRL gene promoter. The hCMV promoter directe
d adenoviral beta -galactosidase expression in all pituitary cell types, bu
t the PRL promoter restricted this exclusively to lactotropic cells, indica
ting that this promoter conferred appropriate cell type specificity in the
context of adenoviral transduction in vivo. Serial measurements of plasma h
ormones showed no disruption of endocrine function over 7 days after intrap
ituitary injection. Ln summary, this work shows cell type-specific expressi
on of an adenoviral transgene in the mixed cell population of the intact pi
tuitary gland in vivo in a large animal model and indicates that stereotaxi
c intrapituitary delivery does not disrupt normal endocrine function.